[The menopausal hormone therapy in 2016].

The menopausal hormone therapy (MHT) is the first line treatment for climacteric symptoms related to estrogen deficiency. A personalized evaluation of the benefit-risk ratio should precede a MHT prescription, and take into consideration cardiovascular, thromboembolic, oncological and osteoporosis risks. MHT should be prescribed at the lowest effective dose and for the shortest duration, respecting the window of opportunity in the 10 years following menopause or before the age of 60 years. The choice of the MHT type depends on the patient's profile, her medical history and personal preferences, with the aim of improving quality of life from a physical, psychological and sexual point of view.